What topics does this cannabis study cover?

This study covers research on: THC, Cancer, Anxiety, Sleep.

Where was this research published?

Published in The oncologist on September 21, 2026.

Pilot trial links higher THC doses with anxiety and insomnia improvement

Q: What did this research study find?

The pilot randomized waitlist-control trial included **32 cannabis-naïve patients** with locally advanced or metastatic pancreatic cancer and compared early versus delayed personalized medical cannabis use over **16 weeks**.

Dose Response Relationship of Medical Cannabis and Symptom Control in Patients With Pancreatic Cancer: An Analysis of the CANPAN Trial.

The oncologist • September 21, 2026 • Highly Relevant

🤖

AI Summary

This abstract-based summary describes a pilot waitlist-control randomized trial examining whether personalized medical cannabis use was related to symptom control in 32 cannabis-naïve patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma. Participants received the intervention either during weeks 0–8 or weeks 9–16, and researchers assessed cannabis use, completion of patient-reported outcomes, and the relationship between daily THC dose and symptoms over the 16-week study period.

Among participants, 23 of 32 (72%) used cannabis during their assigned intervention period. Among those with available data, a higher average daily THC dose was associated with improvements in anxiety and insomnia; this was an association and does not by itself establish that THC caused the improvements. Participants taking at least 10 mg of THC daily had improvement in more symptoms on average than those taking less than 10 mg, although the abstract does not establish a universally effective dose or treatment recommendation.

The main limitation is substantial incomplete follow-up: outcome data at 16 weeks were available for only 16 participants (50%). The authors state that the dose-response findings and this level of data completion will help design future trials, but this pilot analysis cannot firmly establish efficacy, causation, or the best dose. This is an abstract-based summary; the full text was not reviewed.

💡 Key Findings

The pilot randomized waitlist-control trial included 32 cannabis-naïve patients with locally advanced or metastatic pancreatic cancer and compared early versus delayed personalized medical cannabis use over 16 weeks.

High

90%

Cannabis use during the assigned 8-week period was reported by 23 of 32 participants (72%), with similar use patterns in the early and delayed groups.

High

90%

A higher average daily THC dose was associated with improved anxiety and insomnia, but the observational dose relationship does not establish causation.

High

80%

A daily dose of at least 10 mg THC was associated with improvement in more symptoms on average than doses below 10 mg; this is a study finding, not a dosing recommendation.

High

80%

Only 16 participants (50%) had patient-reported outcome data at 16 weeks, limiting what the study can establish about longer-term efficacy and the optimal dose.

High

95%

📄 Original Abstract

BACKGROUND: In a pilot waitlist-control randomized trial, a personalized medical cannabis intervention improved certain symptoms among patients with pancreatic cancer over 8 weeks. Longer-term and dose-response data can guide future trial design. METHODS: CANPAN enrolled 32 cannabis-naïve patients with newly diagnosed locally advanced/metastatic pancreatic adenocarcinoma (NCT06605430). Patients were randomized to early (0-8 weeks) or delayed (9-16 weeks) cannabis intervention. Primary efficacy results over the first 8 weeks were previously reported. We investigated cannabis use and patient-reported outcome (PRO) completion over 9-16 weeks, and the relationship between tetrahydrocannabinol (THC) dose and symptom efficacy. RESULTS: Among 32 participants, 23 (72%) used cannabis during their assigned 8-week period (12/16 in early arm and 11/16 in delayed arm). Of these, 16 (50%) had both pre-cannabis and 8-week post-cannabis initiation PRO data available. At the end of the 16-week study period, PRO data were available for 16 (50%) participants (9/16 early arm, 7/16 delayed arm). Median daily THC dose 4 weeks after starting cannabis was similar in early vs delayed arms (10 mg vs 9.3 mg). A higher average daily THC dose was associated with improvements in anxiety (r 0.52, p = 0.038) and insomnia (r 0.53, p = 0.033). A ≥ 10 mg daily THC dose (vs < 10 mg) was associated with mean improvement in 4 vs 2.1 symptoms. CONCLUSIONS: The 50% complete data availability at 16 weeks, dose-response relationship with psychological symptoms, and threshold dose for multi-symptom efficacy will guide future trials. Similar cannabis use patterns across arms raise confidence in the waitlist-control design.

Paper Type

📄 Research

Publication

Journal: The oncologist
Published: September 21, 2026
PMID: 42767994
DOI: 10.1093/oncolo/oyag374

Authors (7)

Arjun Gupta City of Hope Cancer Center, Phoenix, AZ, USA.
Kendall Lin University of Minnesota, Minneapolis, MN.
Ella Chrenka HealthPartners Institute, Minneapolis, MN.
Grace Gilmore HealthPartners Institute, Cancer Research Center, Minneapolis, MN.
Jordan Cowger HealthPartners Institute, Cancer Research Center, Minneapolis, MN.
+2 more authors